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Abstract
Introduction: Asthma is a chronic airway inflammatory disorder. Nitric oxide (NO) is non-invasively measured in exhaled breath (FeNO). 
The aim of the study was to investigate the anthropometric and physiologic factors that influence FeNO measurements. Also, to 
evaluate FeNO correlation with spirometry and inflammatory markers in asthma and rhinitis.
Material and methods: The study was a prospective analysis of asthma (BA) and rhinitis (AR) in patients enrolled from outpatient 
clinics between 2011 and 2015. Healthy controls (HC) were enrolled from the community. All subjects underwent baseline spirometry 
with reversibility, FeNO measurements, skin prick tests, and blood sampling for absolute eosinophil counts and serum total IgE levels.
Results: Of 528 enrolled participants, 215 were BA, 248 were BA-AR and 65 were HC. The mean FeNO was higher in atopic 
versus nonatopic subjects (34.14 vs. 25.99; p < 0.001); asthmatics versus non-asthmatics (30.46 vs. 12.91; p < 0.001), and in 
participants with BA-AR, compared to those without BA-AR (32.56 vs. 30.46; p < 0.001). The odds ratio for FeNO in the study 
population showed a significant positive association with male gender, absolute eosinophil count (AEC), breathlessness, duration 
of symptoms, family history and atopy. In examining the diagnostic accuracy of FeNO for asthma, the AUC for FeNO value is 0.833 
(95% confidence interval [CI], 0.717–0.901), with cut-off levels to screen for asthma being 19.45 at 71.2% sensitivity and 81.8% 
specificity (p < 0.001). The Positive Predictive Value 96.84% (95% CI: 94.43–98.23) and Negative Predictive Value 30% (95% CI: 
23.78–37.05) for asthma prediction with FeNO. 
Conclusion: The study highlights the importance of estimation of anthropometric parameters and dyspnea assessment in the 
evaluation of FeNO levels. Also, the presence of atopy may influence the results in the interpretation of FeNO readings. Moreover, 
the study have demonstrated that spirometry and FeNO have no significant correlation, which further lays emphasis on them as 
being different physiological parameters of asthma. 
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Introduction
Globally, asthma affects approximately 300 
million individuals with prevalence varying from 
1% to 18% in different geographical regions [1, 2]. 
In India, the prevalence in adults varied from 
0.96% to 11.03%, while in children ranged from 
2.3% to 11.9% [3]. 
Asthma is a chronic airway inflammatory 
disorder, and assessment of airway inflammation 
may have therapeutic implications. The nitric 
oxide (NO) in the lung/airways has a key role as 
a vasodilator, bronchodilator, neurotransmitter, 
and inflammatory mediator [4]. NO is non-inva-
sively measured in exhaled breath (FeNO) and 
has gained substantial, clinical, and scientific 
interest for diagnosis, monitoring, or predicting 
the response to the treatment of airway inflamma-
tion in asthma [5]. Allergic rhinitis patients have 
increased FeNO levels, reflecting the extension of 
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inflammation throughout the airways, a feature in 
the well-known concept of the ‘united airway’ [6]. 
The FeNO level is influenced by anthropo-
metric variables such as age, sex, height, weight 
and body mass index (BMI). Age-dependent in-
crease in FeNO levels has been observed; higher 
levels have been found to be in men than in 
women [7–9]. FeNO significantly correlates with 
height, due to increased lung size with taller 
height [10]. The relationship between BMI and 
FeNO in adults has been inconclusive [11]. 
There is a convincing evidence of an associ-
ation between atopy and FeNO; a positive corre-
lation between FeNO and the number of positive 
skin prick tests has been reported [12–14]. Also, 
serum total IgE (S.T.IgE) correlated with FeNO 
levels in asthmatics [15]. However, the correlation 
of FeNO with spirometry variables has not been 
clearly defined [16, 17].
The objective of this study was to observe 
anthropometric and physiological factors that 
influence FeNO measurements along with its re-
lation to spirometry and inflammatory markers in 
the Indian population, specifically in those with 
asthma and rhinitis. 
Material and methods
This study is a prospective analysis of asth-
ma patients performed over a period of 4 years, 
between 2011 and 2015. 
Study design and demographics 
The diagnosis of asthma and allergic rhinitis 
were based on the Global Initiative for Asthma 
(GINA), and Allergic Rhinitis and its Impact on 
Asthma (ARIA) guidelines respectively [18, 19]. 
The patients diagnosed with bronchial asthma 
(BA) and bronchial asthma with allergic rhinitis 
(BA-AR) were enrolled for the study from the 
outpatient clinics. Healthy controls (HC) were 
enrolled from the community and enquired of pre-
vious episodes of asthma or any physician-based 
diagnosis of asthma; and only those with negative 
answer were included in the study.
The subjects with the inability to satisfac-
torily perform the nitric oxide (NO) maneuver 
were excluded. Other exclusion criteria were 
the following: 1) Smoker (former and current 
smokers); 2) Inhaled/nasal/oral steroid intake in 
the preceding 1 month; 3) Episode of upper or 
lower respiratory tract infection in the preceding 
1 month; and 4) History of urticaria/eczema. 
All subjects underwent investigations, in-
cluding baseline spirometry with reversibility, 
FeNO measurements, skin prick tests, and blood 
sampling for absolute eosinophil counts, and 
serum total IgE levels.
To participate in the study, written informed 
consent was obtained from all subjects/parents 
(in the case of subject’s age < 18 years). The in-
stitutional ethical committee approved the study 
protocol. 
Measurement of FeNO 
The measurement of exhaled NO was per-
formed using NIOX chemiluminescence analyzer 
(Aerocrine AB, Solna, Sweden) in accordance 
with the 2005 ATS/ERS recommendations [20]. 
The patient inserted the mouthpiece, in-
haled through the mouth to total lung capacity 
(TLC) and immediately exhaled at a constant 
flow rate (50 ml/s) to residual volume without 
breath-holding. The duration of exhalation had to 
be sufficient (> 4 seconds in subjects < 12 years 
and > 6 seconds in subjects > 12 years). Repeat-
ed, reproducible exhalations were performed to 
obtain at least 2 NO plateau values that agreed 
within 10% of each other. The mean level of two 
reproducible recordings was used as the result 
value.
Skin prick testing (SPT)
SPT to 58 common aeroallergens was per-
formed in all the patients as per standard guide-
lines to assess for atopy [21]. These are the most 
common aeroallergens in the clinical practice of 
allergy in India [22]. Atopy was defined as a pos-
itive skin prick test (wheal diameter of > 3 mm 
as compared to buffer saline as a control) for at 
least ≥ 1 aeroallergen [21]. 
Measurement of serum total IgE  
and absolute eosinophil counts
Serum Total IgE was estimated by ELISA 
method using MINILYSER-TECAN, Austria, Cal-
biotech kit as per manufacturer’s instructions. 
The number of peripheral blood eosinophils was 
counted in EDTA-containing blood samples using 
an automated analyzer. 
Spirometry with reversibility 
Spirometry was performed on a dry, roll-
ing-seal spirometer of the Benchmark model 
lung function machine (P.K. Morgan, Kent, UK). 
Maximal Expiratory Flow Volume curves were 
obtained as per the ATS recommendations before 
and after bronchodilation. At least 3 technically 
acceptable forced expirations were performed for 
up to 8 tests. The highest forced vital capacity 
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(FVC) and forced expiratory volume in 1 second 
(FEV1) were recorded and percentages of the 
predicted values were calculated [23]. An im-
provement in FEV1 and FVC of at least 12% after 
bronchodilator, compared with the baseline val-
ue, indicates a positive bronchodilator response 
[23]. The severity of spirometric abnormality was 
classified on the basis of forced expiratory volume 
in 1 second (FEV1) [23]. 
Statistical analysis 
Data analysis was performed using SPSS sta-
tistical package version 15.0 for Windows (SPSS, 
Chicago, IL, USA). It was examined for distribu-
tion, and homogeneity of variances was checked 
before applying parametric tests. Quantitative 
variables were compared between 3 groups us-
ing ANOVA / Kruskal-Wallis test and between 2 
groups using unpaired t-test/Mann-Whitney test. 
Qualitative variables were compared using Chi-
square/Fisher’s exact test. Statistical significance 
was set at the conventional 5% level (p < 0.05). 
The univariate analysis of factors associated with 
FeNO was done using Pearson correlation. The 
conventional 5% level (p < 0.05) was considered 
to be statistically significant. To assess the diag-
nostic accuracy of FeNO to predict atopy, we con-
structed receiver-operating-characteristic (ROC) 
curves and calculated the areas-under-the-curve 
(AUC) using 5-fold cross-validation. 
Results
Characteristics of the study population 
Of 528 enrolled participants, 215 were BA, 
248 were BA-AR and 65 were healthy controls. 
The clinical characteristics of the study popula-
tion have been described in Table 1. The spirome-
try parameters of the study population have been 
described in Table 2. 
Factors associated with FeNO 
Men had higher FeNO values (34.14 vs. 26.16; 
p < 0.001) than women. The mean FeNO was 
higher in atopic than in non-atopic patients (34.14 
vs. 25.99; p < 0.001), higher in asthmatics than 
in non-asthmatics (30.46 vs. 12.91; p < 0.001) 
and higher in participants with allergic rhinitis 
compared with those without this disorder (32.56 
vs. 30.46; p < 0.001). The odds ratio for FeNO 
in the study population showed a significant 
positive association with male gender, absolute 
eosinophil count (AEC), breathlessness, duration 
of symptoms, family history and atopy (Table 2). 
Diagnostic accuracy of FeNO for asthma  
and atopy
In determining the diagnostic accuracy of 
FeNO for asthma, the AUC for FeNO value was 
0.833 (95% CI, 0.717–0.901). This places the 
probability of the patient being classified correctly 
as asthmatic at 83.3%. The cut-off level for FeNO 
to screen for asthma was taken as 19.45 at 71.2% 
sensitivity and 81.8% specificity (p < 0.001) (Fig. 
1). The positive predictive value 96.84% (95% CI: 
94.43–98.23) and negative predictive value 30% 
(95% CI: 23.78–37.05) for asthma prediction with 
FeNO. 
In determining the diagnostic accuracy of 
FeNO for atopy, the AUC for FeNO value was 0.648 
(95% CI, 0.599–0.696). This places the probability 
of the patient being classified correctly as SPT 
positive at 64.2%. The cut-off level for FeNO to 
screen for atopy was not taken, as it is not a good 
predictor (p = 0.001) (Fig. 2).
In establishing the diagnostic accuracy of 
FeNO for atopy among asthmatics and HC, the 
FeNO values were [0.662 (95% CI, 0.610–0.714) 
vs. 0.421 (95% CI, 0.281–0.562)]. The cut-off level 
for FeNO to screen for atopy among asthmatics 
and non-asthmatics were not taken, as it is not 
a good predictor (p = 0.001) (Fig. 3A, B).
Discussion
The FeNO level measurement has been val-
idated and standardized for supporting the di-
agnosis in cases of eosinophilic inflammation 
of the airways, bronchial hyper-reactivity, and 
asthma [5]. 
A number of host factors were associated 
with FeNO levels. The most important factors 
were age, gender, race/ethnicity, and atopy. The 
normal range of FeNO levels varies from studies 
in a variety of countries considering the effects 
of these factors. The FeNO range in HC in a study 
from India was 12.73 ± 7.8 ppb, whereas other 
studies of the Chinese, African population, and 
data from asthma, and allergy research group had 
the mean FeNO levels ranging from 20 to 39ppb 
[12, 24–28]. The present study had FeNO levels 
of 12.91 ± 10.35 ppb. 
ATS/ERS guidelines state that there is an 
age-dependent increase in FeNO levels in children 
≤ 12 years of age [20], but there is less agreement 
across the studies regarding the relationship with 
the age of adults. The present study did not find 
correlation with age, which is consistent with 
the literature. FeNO interacted significantly with 
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Age, Mean ± SD 26.7 ± 8.5 25.9 ± 8.6 28.2 ± 6.1
Gender
     Female, Freq (col %) 112 (52.1%) 112 (45.2%) 27 (41.5%)
     Male, Freq (col %) 103 (47.9%) 136 (54.8%) 38 (58.5%)
Symptoms
     Breathlessness, Freq (col %) 200 (93.0%) 237 (95.6%) –
     Wheeze, Freq (col %) 193 (89.8%) 220 (88.7%) –
     Cough, Freq (col %) 195 (90.7%) 219 (88.3%) –
A.E.C.
     Mean ± SD 509.0 ± 298.8 506.9 ± 270.7 127.8 ± 85.8
     Median (IQR) 500 (400) 500 (395) 100 (130)
S.Total IgE
     Mean ± SD 538.2 ± 414.1 681.2 ± 572.5 113.0 ± 68.7
     Median (IQR) 487 (430) 579 (503) 105 (98)
SPT Positive, Freq (col %) 116 (54.0%) 149 (60.1%) 30 (46.2%)
No. of allergens in SPT Positive patients, Mean ± SD 4.8 ± 8.2 3.8 ± 4.9 1.6 ± 2.5
FeNO Value, Mean ± SD 32.2 ± 26.4 33.8 ± 23.1 12.9 ± 10.3
FeNO
    < 19.45, Freq (col %) 62 (28.8%) 64 (25.8%) 54 (83.1%)
    > 19.45, Freq (col %) 153 (71.2%) 184 (74.2%) 11 (16.9%)
FEV1(obs)% , Mean ± SD 83.3 ± 19.2 83.9 ± 16.9 95.7 ± 9.7
FVC(obs)% , Mean ± SD 92.8 ± 15.8 90.9 ± 14.2 100.8 ± 10.5
FEV1/FVC(pred)% , Mean ± SD 77.7 ± 12.9 79.3 ± 12.7 90.3 ± 8.8
Reversibility, Freq (col %) 55 (25.6%) 66 (26.6%) –
Severity of airflow limitation
    No, Freq (col %) 118 (54.9%) 127 (51.2%) 59 (90.8%)
    Mild, Freq (col %) 48 (22.3%) 70 (28.2%) 6 (9.2%)
    Moderate, Freq (col %) 24 (11.2%) 34 (13.7%) –
     Moderately Severe, Freq (col %) 14 (6.5%) 9 (3.6%) –
     Severe, Freq (col %) 8 (3.7%) 6 (2.4%) –
     Very Severe, Freq (col %) 3 (1.4%) 2 (0.8%) –
BMI — body mass index; S.T.IgE — serum total immunoglobulin E; AEC — absolute eosinophil count; FeNO — fraction of exhaled nitric oxide; NS — not significant
height in children and in adults, because of the 
increased lung size with taller height [29]. 
The present study did not reveal a signifi-
cant association of BMI with FeNO. However, 
Maniscalco et al. [30] observed a reduction in 
FeNO in 24 adults with severe obesity, which was 
restored after weight loss. Men have consistently 
higher FeNO levels as compared to women [5]; 
even the present study reports higher FeNO lev-
els in men. Spergel et al. studied the correlation 
between FeNO and monthly symptom scores and 
documented significant correlation (r = 0.646 and 
r2 = 0.417; p < 0.0001); FeNO was also able to 
distinguish between mild and moderate to severe 
persistent asthmatic patients [15]. However, the 
present study did not find any significant corre-
lation of FeNO with duration of symptoms. In a 
study of 222 asthmatics, and 27 HC by Banovicin 
et al. [15], subjects with positive family history for 
allergic diseases (bronchial asthma, allergic rhi-
nitis/rhino conjunctivitis, atopic eczema) showed 
higher FeNO (27. 8 ± 2.8 vs. 20.1 ± 1.8 ppb, p 
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Table 2. Correlation of FeNO values (categorized at cut-off of 19.45) with age, clinical and spirometric characteristics
Characteristic Odds ratio 95% CI p
Lower Upper
Age 0.975 0.949 1.003 0.077
Gender 0.566 0.361 0.887 0.013
BMI (kg/m2) 0.976 0.932 1.021 0.294
Duration of symptoms (years) 1.036 1.011 1.061 0.004
Breathlessness 9.357 2.418 36.214 0.001
Wheeze 1.132 0.471 2.718 0.782
Cough 0.669 0.246 1.821 0.431
Family history 1.637 1.112 2.411 0.013
AEC 1.002 1.001 1.003 0.001
S.Total IgE 1.000 1.000 1.000 0.940
SPT Positive 3.555 1.870 6.758 < 0.001
NO of SPT positive 1.039 0.968 1.115 0.293
FEV1 1.000 0.971 1.030 0.991
FVC 1.006 0.981 1.031 0.643
FEV1/FVC 0.991 0.962 1.020 0.533
Reversibility 0.743 0.390 1.413 0.365
Severity of airflow limitation 0.984 0.694 1.396 0.929
BMI — body mass index; S.T.IgE — serum total immunoglobulin E; AEC — absolute eosinophil count; FeNO — fraction of exhaled nitric oxide; FEV1 — forced expiratory 
volume in 1 second; FVC — forced vital capacity
Figure 1. FeNO values to predict the diagnosis of asthma Figure 2. To determine the diagnostic accuracy of FeNO as a predictor 
of atopy
= 0.067). The same study also reported elevated 
FeNO, which was associated with higher total 
serum IgE levels and eosinophilia. The present 
study confirms the positive correlation of FeNO 
with family history of asthma, and eosinophilia. 
It did not show association with S.T.IgE levels.
Atopy is a clinical definition of an IgE-anti-
body responder, which is a personal tendency to 
become sensitized and produce IgE antibodies in 
response to allergens. 
A strong association between FeNO and ato-
py has been documented in the recent literature 
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Figure 3. A — to determine the diagnostic accuracy of FeNO as a predictor of atopy among asthma subjects; B — to determine the diagnostic 
accuracy of FeNO as a predictor of atopy among healthy controls
[6, 12, 31]. Also, the association between the 
degree of atopy and FeNO levels has been report-
ed [12, 31, 32], with the conclusion that, as the 
number of positive responses to skin prick test 
increases, the FeNO levels also increase [6, 12, 33]. 
This finding has been attributed to the difference 
in inflammatory cell recruitment in atopic (eosin-
ophilic) and non-atopic asthmatics (neutrophilic), 
as well as to cell activity of NO-producing cells 
[28]. In accordance with the literature, the present 
study documented a positive correlation of FeNO 
with atopy. However, FeNO was not a good predic-
tor of atopy among asthmatic and non-asthmatic 
subjects. 
Asthma symptoms are typically caused by 
airflow limitation caused by a narrowed airway. 
FeNO measures airway inflammation that can pro-
duce changes in the lining of the airway, which 
may or may not result in asthma symptoms and 
turbulent airflow from obstruction. FeNO and 
FEV1, therefore, measure different components of 
the asthmatic physiology. In the literature, FeNO 
correlates only with the spirometry parameters 
relating to airflow obstruction present in the small 
airways. Delguidice et al. [34], reported significant 
correlations between FeNO and FEV1 (p < 0.0059, 
r = 0.468), and between FeNO and FEF25–75 
(p < 0.0098, r = 0.439). Similarly, Stănciulescu 
et al. [17], outlined relationship between FeNO 
and MEF25–75 [17]. In the present study, FeNO 
did not show significant negative associations 
with FEV1 and FEV1/FVC. In like manner, in a 
study by Spergel et al. [16], FeNO did not cor-
relate with FEV1 reflecting the fact that these 2 
parameters measure different aspects of asthma. 
The limitation of the present study was that 
the exposure to allergen at the time of FeNO 
measurement was not documented. Also, a larg-
er number of control subjects could have been 
recruited for establishment of factors affecting 
FeNO measurement.
Conclusion
The study highlights the importance of esti-
mation of anthropometric parameters and dysp-
nea assessment in the evaluation of FeNO levels. 
Also, the presence of atopy may influence the 
results in the interpretation of FeNO readings. 
Furthermore, the study has demonstrated that 
spirometry and FeNO have no significant correla-
tion, which further lays emphasis on them as be-
ing different physiological parameters of asthma. 
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